# Critical Path for Parkinson's (CPP)
> A global public-private partnership, initiated by Critical Path Institute with founding partners like Parkinson's UK, dedicated to accelerating the development and regulatory approval of therapies for Parkinson's disease. It achieves this by fostering collaboration, sharing data, and developing novel drug development tools to improve the lives of people with Parkinson's worldwide. This program serves as an international collaboration framework, offering a global approach to Parkinson's research and drug development.
- URL: https://optimly.ai/brand/parkinsons-uk-international-equivalent
- Logo: https://logo.clearbit.com/https://c-path.org/program/critical-path-for-parkinsons/
- Slug: parkinsons-uk-international-equivalent
- BAI Score: 55/100
- Archetype: Incumbent
- Category: Healthcare
- Last Analyzed: July 26, 2026
## Buyer Intent Signals
Problems: Individual Research and Data Analysis: Researchers and pharmaceutical companies would individually collect, standardize, and analyze data from various sources, leading to fragmented insights, slower p | Contract Research Organizations (CROs): CROs could manage clinical trials and data analysis on a project-by-project basis. However, they may lack the broad, multi-stakeholder collaborative framework,  | Status Quo (Fragmented Drug Development): Without CPP's initiatives, drug development for Parkinson's would remain more fragmented, less efficient, and potentially less patient-centric due to a lack o
Solutions: Critical Path for Parkinson's | C-Path Parkinson's program | Parkinson's drug development collaboration | General Scientific Data Platforms: While general data platforms can store and analyze scientific data, they typically lack the disease-specific standardization, regulatory guidance, and pre-competitiv